Status:
RECRUITING
Impaired Type I IFN Immunity Due to Autoantibodies or a Genetic Defect: a Prospective National Cohort
Lead Sponsor:
Institut National de la Santé Et de la Recherche Médicale, France
Conditions:
Immunology
Allergy
Eligibility:
All Genders
18+ years
Brief Summary
The major role of human genetic factors in the immune response to infections is now well established, particularly for viral infections. In the context of the COVID-19 pandemic, the following results ...
Eligibility Criteria
Inclusion Criteria:
- Age >18 years
- History of carrying 1) auto-Abs against type I IFNs or 2) IEI impairing the response to, or the production of, type I IFNs (IFN-I-IEI)
- Affiliated to social security
- Written informed consent
Exclusion Criteria:
- Participation to an interventional clinical trial on a pharmacological treatment
- Clinical condition leading to life expectancy less than 1 year
- Subject to a legal protection measure (safeguard of justice, curatorship, tutorship)
- Individuals deprived of freedom
Key Trial Info
Start Date :
April 9 2025
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
January 1 2029
Estimated Enrollment :
500 Patients enrolled
Trial Details
Trial ID
NCT06762002
Start Date
April 9 2025
End Date
January 1 2029
Last Update
September 8 2025
Active Locations (9)
Enter a location and click search to find clinical trials sorted by distance.
1
Cic Lille
Lille, France
2
LYON HCL
Lyon, France
3
Cic Montpellier
Montpellier, France
4
Cic Bichat
Paris, France